Gout & crystal arthropathies

Results from a prospective cohort study suggest that increased levels of serum CA72-4 at urate-lowering therapy initiation are an independent risk factor for recurrent gout flares.

The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.

SGLT2 inhibitors, a type of diabetes drug, are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

Individuals with rheumatic conditions living in areas with the highest social and heat vulnerability are significantly more likely to experience recurrent hospitalizations than those living in the least vulnerable areas, research suggests.

The higher prevalence of gout among Black men and women than their White counterparts is related to diet, social determinants of health, and chronic kidney disease, indicates research published in JAMA Network Open.

Gout flares are associated with an increased risk for cardiovascular events in the following 120 days, study findings suggest.

Regular allopurinol use and keeping serum urate levels within the target range may be associated with a reduced risk for cardiovascular events in men with gout and no history of cardiovascular disease, observational study findings indicate.

A transdermal alkalinizing and pain-relieving treatment has been shown to effectively reduce the pain intensity and duration of an acute gout flare in the phase 2 TARGET study.

The addition of methotrexate to pegloticase for the treatment of uncontrolled gout improves the rate of sustained urate-lowering response over 6 months, show findings from the MIRROR randomized controlled trial.

Supported self-management improves attainment of urate targets in people with gout, research suggests.

COVID-19 vaccination with inactivated virus vaccines is associated with an increased risk for flares among men with gout, and colchicine prophylaxis may help reduce this risk, researchers report.

Study findings published in Rheumatology show that long-term use of colchicine is associated with a decreased risk for adverse renal outcomes in people with hyperuricemia or chronic gout and stage G3–G4 chronic kidney disease.

People with gout, particularly women, may have an elevated risk for COVID-19 diagnosis and related death, suggest the results of a population-based study reported in The Lancet Rheumatology.

EULAR has issued recommendations for managing cardiovascular risk in people with antiphospholipid syndrome, gout, mixed connective tissue disease, myositis, Sjögren’s syndrome, systemic lupus erythematosus, systemic sclerosis, or vasculitis.